Mosaic ImmunoEngineering, Inc. CPMV
Set alert
0.06 USD -0.08 -56.20%
At close · Oct 30
0.06 Day range 0.06
0.054 52-week range 0.89
- YTD
- -80.71%
- 1 year
- -92.84%
- Open
- 0.06
- Prev close
- 0.137
- Mkt cap
- 434.53K
- Vol
- 2
- Avg vol
- 468
- EPS
- -0.10
- P/E
- 0.00
More statistics
- Low
- 0.06
- High
- 0.06
- Earnings
- Nov 2, 2023
1Y chart
Signals (81)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 2026 | 1 day ago |
| SMA: Bullish | Oct 26, 2026 | 1 week ago |
| SMA: Bearish | Oct 22, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 22, 2026 | 1 week ago |
| SMA: Bullish | Oct 9, 2026 | 3 weeks ago |
| RSI: Overbought | Oct 9, 2026 | 3 weeks ago |
| MACD: Buy Signal | Aug 31, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 13, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
| RSI: Oversold | Jul 30, 2026 | 3 months ago |
| SMA: Bearish | Jul 27, 2026 | 3 months ago |
| SMA: Bearish | Jul 27, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 27, 2026 | 3 months ago |
| RSI: Oversold | Jul 27, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 23, 2026 | 3 months ago |
| SMA: Bullish | Jul 22, 2026 | 3 months ago |
| SMA: Bearish | Jul 9, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 8, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 8, 2026 | 4 months ago |
| SMA: Bullish | Jun 3, 2026 | 5 months ago |
Newest 20 of 81.
Next earnings
Nov 2, 2023
Expected Nov 2, 2023. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 19, 2024 | Sep 1, 2024 | 0.00 | -0.03 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -0.04 | — | — |
| Apr 15, 2024 | Dec 1, 2023 | 0.00 | -0.04 | — | — |
| Nov 2, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Aug 3, 2023 | Jun 1, 2023 | 0.00 | 0.00 | — | — |
| Nov 1, 2022 | Sep 1, 2022 | 0.00 | -0.02 | — | — |
News
- Mosaic ImmunoEngineering (OTCMKTS:CPMV) Stock Jumps 432.8% – Here’s Why
- Mosaic ImmunoEngineering Inc. (OTCMKTS:CPMV) Short Interest Update
- Mosaic ImmunoEngineering Agrees to Acquire Clinical Necroptosis Cancer Therapy Assets from Oncotelic Therapeutics, Inc.
- Mosaic ImmunoEngineering Expands Immuno-Oncology Platform Through New Technology Licensing Agreement with the University of California San Diego
- Upcoming Presentation at the World Molecular Imaging Congress to Highlight Mosaic ImmunoEngineering's Lead Immuno-Oncology and Modular Vaccine Platform COVID-19 Vaccine Candidates
- Mosaic ImmunoEngineering Announces Keynote Presentation Highlighting its Modular Vaccine Platform Delivery Technology
- Mosaic ImmunoEngineering Announces Publication of Data Supporting the Potential of Its SARS-CoV-2 Vaccine Candidates under its Modular Vaccine Platform
- Mosaic ImmunoEngineering Expands Its Modular Vaccine Platform (MVP) Through New Technology Licensing Agreement with the University of California San Diego
- Newly Published Preclinical Data Highlight Broad Immune Activation of Mosaic ImmunoEngineering's Lead Intratumoral Immunotherapy Candidate, MIE-101
- Mosaic ImmunoEngineering Submits Application for Nasdaq Uplisting
Your note
Sign in to keep a note on CPMV — it syncs with the Stock Master app.